The American Journal of Medicine
Volume 122, Issue 11 , Pages 1016-1022.e1 , November 2009

Bayesian Meta-analysis of Hormone Therapy and Mortality in Younger Postmenopausal Women

  • Shelley R. Salpeter, MD

      Affiliations

    • Santa Clara Valley Medical Center, San Jose, Calif
    • Stanford University, Palo Alto, Calif
    • Corresponding Author InformationRequests for reprints should be addressed to Shelley R. Salpeter, MD, Santa Clara Valley Medical Center, 751 S. Bascom Ave, San Jose, CA 95128
    • ,
  • Ji Cheng, MSc

      Affiliations

    • McMaster University, Hamilton, Ontario, Canada
    • ,
  • Lehana Thabane, PhD

      Affiliations

    • McMaster University, Hamilton, Ontario, Canada
    • ,
  • Nicholas S. Buckley

      Affiliations

    • California Institute of Technology, Pasadena
    • ,
  • Edwin E. Salpeter, PhD (Posthumous)

      Affiliations

    • Cornell University, Ithaca, NY

References 

  1. Wallach S, Henneman PH. Prolonged estrogen therapy in postmenopausal women. J Am Med Assoc. 1959;171:1637–1642
  2. Robinson RW, Higano N, Cohen WD. Increased incidence of coronary heart disease in women castrated prior to the menopause. Arch Intern Med. 1959;104:908–913
  3. Wilson RA, Brevetti RE, Wilson TA. Specific procedures for the elimination of the menopause. West J Surg Obstet Gynecol. 1963;71:110–121
  4. Bush TL, Cowan LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality (Preliminary results from the Lipid Research Clinics Program Follow-Up Study). JAMA. 1983;249:903–906
  5. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol. 1987;70(3 Pt 1):289–293
  6. Cauley JA, Seeley DG, Browner WS, et al. Estrogen replacement therapy and mortality among older women (The study of osteoporotic fractures). Arch Intern Med. 1997;157:2181–2187
  7. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769–1775
  8. Paganini-Hill A, Corrada MM, Kawas CH. Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort Study. Menopause. 2006;13:12–18
  9. Mishell DR. Estrogen replacement therapy: an overview. Am J Obstet Gynecol. 1989;161(6 Pt 2):1825–1827
  10. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  11. Salpeter SR, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004;19:791–804
  12. Furburg CD, Psaty BM. Review: hormone replacement therapy may reduce the risk for death in younger but not older postmenopausal women. ACP J Club. 2005;142:1
  13. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women (A meta-analysis). J Gen Intern Med. 2006;21:363–366
  14. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–1477
  15. Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med. 2009;122:42–52
  16. Whitehead A. Meta-analysis of Controlled Clinical Trials. Chichester, England: John Wiley & Sons; 2002;
  17. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-care Evaluation. Chichester, England: John Wiley & Sons; 2004;
  18. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res. 2001;10:277–303
  19. Sung L, Hayden J, Greenberg ML, et al. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol. 2005;58:261–268
  20. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med. 2002;21:1601–1623
  21. Lambert PC, Sutton AJ, Burton PR, et al. How vague is vague? (A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS). Stat Med. 2005;24:2401–2428
  22. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med. 1996;15(24):2733–2749
  23. Higgins JP, Spiegelhalter DJ. Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction. Int J Epidemiol. 2002;31:96–104
  24. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet. 1998;351(9095):47–52
  25. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102–1109
  26. Criqui MH, Suarez L, Barrett-Connor E, et al. Postmenopausal estrogen use and mortality (Results from a prospective study in a defined, homogeneous community). Am J Epidemiol. 1988;128:606–614
  27. Folsom AR, Mink PJ, Sellers TA, et al. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health. 1995;85(8 Pt 1):1128–1132
  28. Stahlberg C, Lynge E, Andersen ZJ, et al. Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy—a prospective observational study. Int J Epidemiol. 2005;34:931–935
  29. Angerer P, Kothny W, Stork S, von Schacky C. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial. J Am Coll Cardiol. 2000;36:1789–1796
  30. Arrenbrecht S, Boermans AJ. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial. Osteoporos Int. 2002;13:176–183
  31. Giske LE, Hall G, Rud T, Landgren BM. The effect of 17beta-estradiol at doses of 0.5, 1 and 2 mg compared with placebo on early postmenopausal bone loss in hysterectomized women. Osteoporos Int. 2002;13:309–316
  32. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer. 1999;86:1013–1018
  33. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 1994;37:1499–1505
  34. Hall G, Pripp U, Schenck-Gustafsson K, Landgren BM. Long-term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas. 1998;28:235–242
  35. Komulainen M, Kroger H, Tuppurainen MT, et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. J Clin Endocrinol Metab. 1999;84:546–552
  36. Kyllonen ES, Heikkinen JE, Vaananen HK, et al. Influence of estrogen-progestin replacement therapy and exercise on lumbar spine mobility and low back symptoms in a healthy early postmenopausal female population: a 2-year randomized controlled trial. Eur Spine J. 1998;7:381–386
  37. Lindsay R, Hart DM, Aitken JM, et al. Long-term prevention of postmenopausal osteoporosis by oestrogen (Evidence for an increased bone mass after delayed onset of oestrogen treatment). Lancet. 1976;1(7968):1038–1041
  38. MacDonald AG, Murphy EA, Capell HA, et al. Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis. 1994;53:54–57
  39. Mijatovic V, Netelenbos C, van der Mooren MJ, et al. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril. 1998;70:1085–1089
  40. Mosekilde L, Beck-Nielsen H, Sorensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas. 2000;36:181–193
  41. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979;54:74–79
  42. PEPI Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women (The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial). JAMA. 1995;273:199–208
  43. Perez-Jaraiz MD, Revilla M, Alvarez de los Heros JI, et al. Prophylaxis of osteoporosis with calcium, estrogens and/or eelcatonin: comparative longitudinal study of bone mass. Maturitas. 1996;23:327–332
  44. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study (A randomized, controlled trial). Ann Intern Med. 1999;131:935–942
  45. Watts NB, Nolan JC, Brennan JJ, Yang HM. Esterified estrogen therapy in postmenopausal women (Relationships of bone marker changes and plasma estradiol to BMD changes: a two-year study). Menopause. 2000;7:375–382
  46. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712
  47. Utian WH. NIH and WHI: time for a mea culpa and steps beyond. Menopause. 2007;14:1056–1059
  48. Pines A, Sturdee DW, Birkhauser MH, et al. HRT in the early menopause: scientific evidence and common perceptions (Summary of the First IMS Global Summit on menopause-related issues). http://www.imsociety.org/pdf_files/comments_and_press_statements/ims_press_statement_13_05_08.pdf?SESSID=qr3rsun20036dp70id40v17m87March 29-30, 2008;Accessed June 15, 2008
  49. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–427
  50. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 2002;360(9337):942–944
  51. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933–941
  52. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872–881
  53. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356:2591–2602
  54. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ. 2005;330(7487):342
  55. Zethraeus N, Johannesson M, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol. 1997;104:1191–1195
  56. Smith AJ, Hall DR, Grove D. Postmenopausal hormone therapy and quality of life. Int J Gynaecol Obstet. 2006;95:267–271
  57. Dinger J, Zimmermann T, Heinemann LA, Stoehr D. Quality of life and hormone use: new validation results of MRS scale. Health Qual Life Outcomes. 2006;4:32
  58. Ylikangas S, Sintonen H, Heikkinen J. Decade-long use of continuous combined hormone replacement therapy is associated with better health-related quality of life in postmenopausal women, as measured by the generic 15D instrument. J Br Menopause Soc. 2005;11:145–151
  59. Heikkinen J, Vaheri R, Timonen U. A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: update of safety and quality-of-life findings. J Br Menopause Soc. 2006;12:115–125
  60. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med. 2002;137:834–839
  61. North American Menopause Society. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause. 2003;10(1):6–12
  62. Wathen CN, Feig DS, Feightner JW, et al. Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ. 2004;170:1535–1537
  63. Pines A, Sturdee DW, Birkhauser MH, et al. IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007;10:181–194
  64. North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause. 2007;14:168–182

 Funding: No research funding.

 Conflict of Interest: Dr. Salpeter has consulted in the past with law firms representing Wyeth Pharmaceuticals on issues involving hormone therapy, and was paid on an hourly basis. Dr. Thabane consults with GlaxoSmithKline on statistical and methodological issues. The other authors report no potential conflicts of interest.

 Authorship: All authors had access to the data and had a role in writing the manuscript. Edwin Salpeter died after the preparation and approval of the manuscript.

PII: S0002-9343(09)00666-4

doi: 10.1016/j.amjmed.2009.05.021

The American Journal of Medicine
Volume 122, Issue 11 , Pages 1016-1022.e1 , November 2009

Article Tools

* Image Usage & Resolution